BioSpace News Archive

Lexogen is proud to be featured in Nature Methods with a Technical Application Note in the November edition of this esteemed journal.

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced new data from the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry that showed a substantial proportion of people living with treatment-resistant active PsA and using TREMFYA® (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months.

Corner Therapeutics announced the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines.

Morphogenesis, Inc. announced positive biomarker analysis data from its first-in-human study evaluating IFx-Hu2.0 for patients with melanoma refractory to anti-PD1-based therapies.

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab.

Allgenesis Biotherapeutics Inc. presented exciting preliminary data from the first-in-human, Phase 2a clinical trial assessing the safety, tolerability, and efficacy of AG-73305 in Diabetic Macular Edema (DME) patients.

Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).

Sfunga Therapeutics (“Sfunga”), a biotechnology company, and Deerfield Management Company (“Deerfield”), a healthcare investment firm, today announced the publication of data on a novel antifungal molecule AM2-19 in the scientific journal Nature.

The global pharmaceutical intermediates market size was estimated at around USD 2.38 billion in 2022 and it is projected to hit around USD 4.74 billion by 2032, growing at a CAGR of 7.14% from 2023 to 2032.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported financial results for the third quarter ended September 30, 2023 and provided recent corporate and clinical updates.